Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00848289 · ClinicalTrials.gov registry record
Genetic Susceptibility to Bladder Cancer
A clinical trial of Bladder Cancer, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- 6,086
- Enrollment target
- 2
- Study locations
NCT00848289 is a study of Bladder Cancer that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 6,086 participants, below the 12,719-participant average among 175 other Bladder Cancer trials with a reported enrollment target (52% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00848289, a study of Bladder Cancer, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 6,086 participants
- Enrollment target
- 2
- Study locations
Study Summary
This clinical research study will identify biologic and lifestyle factors which increase a person's risk of developing specific cancer. Researchers propose to conduct a case-control study examining interindividual differences in susceptibility to tobacco carcinogenesis as predictors of bladder cancer risk. We will measure susceptibility to tobacco carcinogenesis and this will include studies of the genetic modulation of carcinogen activation and detoxification and of chromosome sensitivity to tobacco mutagens.
Conditions Studied
Interventions
- BEHAVIORAL Interviews
Study Locations (2)
Texas
- Baylor College of Medicine - Houston
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,086 participants |
| Start Date | 1998-02-10 |
| Est. Completion | 2026-08-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00848289
The ClinicalTrials.gov registry entry for NCT00848289 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 6,086 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,719-participant average among 175 other Bladder Cancer trials with a reported enrollment target (52% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which Interviews is the first listed.
NCT00848289 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00848289 about?
NCT00848289 is a clinical study titled "Genetic Susceptibility to Bladder Cancer". This clinical research study will identify biologic and lifestyle factors which increase a person's risk of developing specific cancer. Researchers propose to conduct a case-control study examining interindividual differences in susceptibility to tobacco carcinogenesis as predictors of bladder cance...
What is the current status of trial NCT00848289?
This trial is currently active not recruiting. The enrollment target is 6,086 participants. The study started on 1998-02-10. Estimated completion is 2026-08-01.
What conditions does trial NCT00848289 study?
This clinical trial studies the following conditions: Bladder Cancer.
What interventions are being tested in trial NCT00848289?
The interventions under investigation include: Interviews (BEHAVIORAL).
Who is sponsoring clinical trial NCT00848289?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00848289 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.